Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial
Cabergoline significantly reduced monthly migraine days in episodic migraine without serious adverse effects, supporting further investigation into the use of cabergoline for migraine prevention.
Authors
- Flemming W. Bach (ORCID: https://orcid.org/0000-0002-2518-9335)
- Henrik Støvring (ORCID: https://orcid.org/0000-0002-5821-2351)
- Helge Kasch (ORCID: https://orcid.org/0000-0002-9302-4946)
- Troels S. Jensen (ORCID: https://orcid.org/0000-0002-3487-6380)
- Jens Otto Lunde Jørgensen (ORCID: https://orcid.org/0000-0001-7408-1526)
- Astrid Johannesson Hjelholt (ORCID: https://orcid.org/0000-0002-3114-4176)
Institutions
- Steno Diabetes Centers (DK)
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1371/journal.pone.0320937
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Aarhus Universitet